

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:


File Information Unit

Crystal Plaza Three, Room 1D01

2021 South Clark Place

Arlington, VA

Telephone: (703) 308-2733



In re Application of

Application Number

07746 D20

Filed

Aug 15, 1991

Paper No. #16

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified **ABANDONED** application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____.

United States Patent Number 5541204, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.

Darlene Jones
 Signature

Darlene Jones
 Typed or printed name

April 02 04
 Date

Registration Number, if applicable

(703) 418-0330

Telephone Number

FOR PTO USE ONLY.

Approved by *[Signature]*

(Initials)

Unit:

APR 02 2004

File Information Unit

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1D01, 2021 South Clark Place, Arlington, VA.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US005541206A

United States Patent [19]**Kempf et al.**[11] **Patent Number:** **5,541,206**[45] **Date of Patent:** **Jul. 30, 1996**[54] **RETROVIRAL PROTEASE INHIBITING COMPOUNDS**[75] **Inventors:** Dale J. Kempf, Libertyville; Daniel W. Norbeck, Crystal Lake; Hing Leung Sham; Chen Zhao, both of Gurnee, all of Ill.[73] **Assignee:** Abbott Laboratories, Abbott Park, Ill.[21] **Appl. No.:** 423,387[22] **Filed:** Apr. 25, 1995**Related U.S. Application Data**

[63] **Continuation of Ser. No. 158,587, Dec. 2, 1993, abandoned, which is a continuation-in-part of Ser. No. 998,114, Dec. 29, 1992, abandoned, which is a continuation-in-part of Ser. No. 777,626, Oct. 23, 1991, abandoned, which is a continuation-in-part of Ser. No. 746,020, Aug. 15, 1991, abandoned, which is a continuation-in-part of Ser. No. 616,170, Nov. 20, 1990, abandoned, which is a continuation-in-part of Ser. No. 518,730, May 9, 1990, Pat. No. 5,142,056, which is a continuation-in-part of Ser. No. 456,124, Dec. 22, 1989, abandoned, which is a continuation-in-part of Ser. No. 405,604, Sep. 8, 1989, abandoned, which is a continuation-in-part of Ser. No. 355,945, May 23, 1989, abandoned.**

[51] **Int. Cl.** A61K 31/425; C07D 413/12; C07D 417/12[52] **U.S. Cl.** 514/365; 548/204; 548/194; 548/187; 548/235; 548/227; 548/228; 548/229; 514/374; 514/369; 514/370; 514/376; 514/377[58] **Field of Search** 514/365, 374, 514/369, 370, 376, 377; 548/204, 194, 187, 235, 227, 228, 229[56] **References Cited****U.S. PATENT DOCUMENTS**

5,354,866 10/1994 Kempf et al. 546/265

FOREIGN PATENT DOCUMENTS

346847B1 12/1989 European Pat. Off.
 393445B2a 10/1990 European Pat. Off.
 393445B2 10/1990 European Pat. Off.
 402646B6 12/1990 European Pat. Off.


428849B12 5/1991 European Pat. Off.
 428849B12a 5/1991 European Pat. Off.
 441192B3 8/1991 European Pat. Off.
 441192B3a 8/1991 European Pat. Off.
 486948B5 5/1992 European Pat. Off.
 3829594B1a 3/1990 Germany
 3829594B1 3/1990 Germany
 4003575B4 8/1992 Germany
 4003575B4a 8/1992 Germany
 WO88/02374B7 4/1988 WIPO
 WO92/00948B9 8/1990 WIPO
 WO90/09191B8a 8/1990 WIPO
 WO90/09191B8 8/1990 WIPO
 WO91/18866B10 12/1991 WIPO
 WO92/06996B11 4/1992 WIPO
 WO92/20665B13 11/1992 WIPO
 WO93/01174B14 1/1993 WIPO

OTHER PUBLICATIONS

Wade Jr. Organic Chemistry p. 349 1987 by Prentice-Hall, Inc.

Zeffren et al. The Study of Enzyme Mechanism, p. 87. 1974.
 Shutske et al. J. Med. Chem. 1989. 32. 1805-1813.**Primary Examiner**—Jane Fan**Attorney, Agent, or Firm**—Steven R. Crowley[57] **ABSTRACT**

A retroviral protease inhibiting compound of the formula:



is disclosed.

19 Claims, No Drawings

Do
NOT
NEED

PLEASE
GET

DO
NOT
NEED